Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 19/20 | 0.55 |
| ▸ | CDK2 | P24941 | 19/20 | 0.55 |
| ▸ | CCND1 | P24385 | 12/20 | 0.52 |
| ▸ | CDK6 | Q00534 | 12/20 | 0.52 |
| ▸ | CDK4 | P11802 | 8/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.52 |
| ▸ | CDK9 | P50750 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855986 | 0.82 | NOS2 (0.61) | CDK2CCND1CDK4ALDH1A1 | |
| SCHEMBL14003195 | 0.81 | MAPK8 (0.67) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL31538947 | 0.80 | CDK2 (0.62) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL1517393 | 0.77 | CCNE1 (0.53) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL1516739 | 0.77 | CDK2 (0.55) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL1517016 | 0.75 | CDK2 (0.55) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL4899133 | 0.75 | MAPK8 (0.69) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL4857693 | 0.74 | PDE3B (0.45) | ALDH1A1 | |
| SCHEMBL1517517 | 0.73 | CDK2 (0.55) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30838835 | 0.72 | CDK2 (0.65) | CCNE1CDK2CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456185-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | DUNN JAMES P | 2007-07-19 | — | — | US | disclosed |
| US-7238698-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | MAPK1, MAPK7, MAPK3 | CCNE1 747/4885CDK2 245/4885CCND1 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.